Literature DB >> 9531347

Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin.

K H Yeh1, A L Cheng.   

Abstract

Acute disseminated intravascular coagulation (DIC) is a severe complication of gastric adenocarcinoma, and most of the patients die within 1-3 weeks. We have treated five such patients with an empirical non-myelosuppressive HDFL regimen (weekly 24h infusion of high-dose 5-fluorouracil 2600 mg/m2 and leucovorin 300 mg/m2). Within 2 weeks of starting the treatment the clinical and laboratory evidence of acute DIC quickly resolved in all five patients. HDFL not only caused no further myelosuppression, but also resulted in normalization of the patient's haemogram within a few weeks. Other anti-cancer drugs could then be safely added. Three patients had a survival time of more than 6 months. We suggest that HDFL is an ideal initial treatment for gastric cancer complicated by acute DIC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531347     DOI: 10.1046/j.1365-2141.1998.00613.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Bone metastasis as the first sign of gastric cancer.

Authors:  Wafa Ben Ameur; Safa Belghali; Imen Akkari; Houneida Zaghouani; Elyes Bouajina; Elhem Ben Jazia
Journal:  Pan Afr Med J       Date:  2017-09-29

2.  Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.

Authors:  K H Yeh; S H Yeh; C H Hsu; T M Wang; I F Ma; A L Cheng
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

3.  An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer.

Authors:  Y Chao; C P Li; T Y Chao; W C Su; R K Hsieh; M F Wu; K H Yeh; W Y Kao; L T Chen; A L Cheng
Journal:  Br J Cancer       Date:  2006-06-27       Impact factor: 7.640

4.  Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.

Authors:  K H Yeh; Y S Lu; C H Hsu; J F Lin; H J Chao; T C Huang; C Y Chung; C S Chang; C H Yang; A L Cheng
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

5.  Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.

Authors:  Hei-Cheul Jeung; Sun Young Rha; Sang Joon Shin; Joong Bae Ahn; Sung Hoon Noh; Jae Kyung Roh; Hyun Cheol Chung
Journal:  Jpn J Clin Oncol       Date:  2009-10-31       Impact factor: 3.019

6.  Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer.

Authors:  Y Chao; K H Yeh; C J Chang; L T Chen; T Y Chao; M F Wu; C S Chang; J Y Chang; C Y Chung; W Y Kao; R K Hsieh; A L Cheng
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

7.  Advanced Gastric Cancer Associated with Disseminated Intravascular Coagulation Successfully Treated with 5-fluorouracil and Oxaliplatin.

Authors:  Dong Seok Lee; Seung Jin Yoo; Ho Suk Oh; Eun Jung Kim; Kwang Hoon Oh; Sang Jin Lee; Jong Kyu Park; Yong Chel Ahn; Dae-Woon Eom; Heui June Ahn
Journal:  J Gastric Cancer       Date:  2013-06-25       Impact factor: 3.720

8.  Chemotherapy in advanced gastric cancer patients associated with disseminated intravascular coagulation.

Authors:  In Gyu Hwang; Jin Hwa Choi; Se Hoon Park; Sung Yong Oh; Hyuk-Chan Kwon; Soon Il Lee; Do Hyoung Lim; Gyeong-Won Lee; Jung Hun Kang
Journal:  Cancer Res Treat       Date:  2014-01-15       Impact factor: 4.679

9.  Routine Hemostasis and Hemogram Parameters: Valuable Assessments for Coagulation Disorder and Chemotherapy in Cancer Patients.

Authors:  Ying-Wei Zhu; Tong-Bao Feng; Xian-Ju Zhou; Xue-Li Hu; Jie Ding; Wen-Yu Zhu; Dan-Ping Qian; Yi-Wu Sun
Journal:  Chin Med J (Engl)       Date:  2016-08-05       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.